WuXi AppTec acquires preclinical CRO

By Melissa Fassbender

- Last updated on GMT

iStock/Sean_Kuma
iStock/Sean_Kuma

Related tags Corporation Subsidiary

WuXi AppTec has acquired Shanghai-based HD Biosciences (HDB), a biology-focused preclinical contract research organization (CRO). 

HD Biosciences, which also has facilities in Beijing and the US, will become a wholly-owned subsidiary of WuXi.

According to WuXi AppTec, the acquisition will strengthen the company’s research and development capabilities from target validation to lead discovery and optimization.

HD Biosciences’ capabilities include plate-based pharmacology and screening as well as AGMTM based target validation.

In a press statement, Dr. Xuehai Tan, Chairman and CEO of HD Biosciences, said the integration of services will enable the company to meet its growing customer needs.

Related topics Preclinical Research Preclinical

Related news

Show more

Related products

Small Molecule development – getting it right

Small Molecule development – getting it right

Content provided by Lonza Small Molecules | 20-Jun-2023 | Insight Guide

Small Molecule drug development is something more and more ambitious emerging pharmaceutical companies are taking on from end to end. But this path can...

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Content provided by Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

Related suppliers

Follow us

Products

View more

Webinars